NASDAQ: TLSITrisalus Life Sciences Inc Stock
$3.03+0.35 (+13.06%)
Updated May 18, 2026
TLSI Price
$3.03
Fair Value Price
N/A
Market Cap
$186.09M
52 Week Low
$2.20
52 Week High
$7.95
P/E
-2.3x
P/B
14.53x
P/S
4.59x
PEG
N/A
Dividend Yield
N/A
Revenue
$44.88M
Earnings
-$27.31M
Gross Margin
85.1%
Operating Margin
-47.98%
Profit Margin
-128.7%
Debt to Equity
4.54
Operating Cash Flow
-$20M
Beta
0.23
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TLSI Overview
MedTech Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the healthcare sector in the U.S. MedTech Acquisition was incorporated in 2020 and is headquartered in Greenwich, CT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TLSI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
TLSI
Ranked#58 of 96
Ranked#58 of 96
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.63 | A | |
| $38.24 | A | |
| $23.65 | A |
Be the first to know about important TLSI news, forecast changes, insider trades & much more!
TLSI News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TLSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLSI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TLSI is poor value based on its book value relative to its share price (14.53x), compared to the US Medical Devices industry average (3x)
P/B vs Industry Valuation
TLSI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TLSI due diligence checks available for Premium users.
Valuation
TLSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.3x
Industry
23.18x
Market
23.29x
TLSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
14.53x
Industry
3x
TLSI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLSI's financial health
Profit margin
Revenue
$8.9M
Net Income
$1.5M
Profit Margin
17.3%
TLSI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TLSI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$71.0M
Liabilities
$58.2M
Debt to equity
4.54
TLSI's short-term assets ($68.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLSI's short-term assets ($68.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLSI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.5M
Investing
-$141.0k
Financing
$42.4M
TLSI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLSI vs Medical Device Stocks
Trisalus Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.